Panel of experts discuss survivorship challenges and potential areas for study.

by Marci A. Landsmann

At the AACR Annual Meeting, researchers and regulators discuss what it means to tie approval of an immunotherapy to tumors' molecular characteristics, not to their tissues of origin.

by Kate Yandell

At the AACR Annual Meeting 2018, researchers at Google compared the speed and accuracy of human pathologists and computer algorithms in diagnosing and grading cancer.

by Kevin McLaughlin

A trio of clinical trials at the AACR Annual Meeting spotlight new avenues for non-small cell lung cancer treatment.

by Brad Jones

Cancer researchers and patient advocates spoke about progress against cancer at a public education forum sponsored by the American Association for Cancer Research.

by Kevin McLaughlin

In a phase III clinical trial, pembrolizumab yielded a 75.4 percent recurrence-free survival rate after 12 months among patients whose stage III melanoma tumors had been fully resected.

by Brad Jones

AACR’s Scientist↔Survivor Program marks a milestone as patient advocates continue to shape research and policy.

by Marci A. Landsmann

Two graduates of the AACR Scientist↔Survivor Program share tips for getting the most out of large scientific conferences.

by Bob Riter and Carole Baas

Patients who opt for breast reconstruction after mastectomy tend to overestimate how happy they will be with the results, while those who do not get reconstruction tend to underestimate their future satisfaction.

by Cici Zhang

Researchers say a next-generation sequencing test could improve screening in colorectal cancer patients for a hereditary syndrome that raises cancer risk. Some experts have concerns.

by Cheryl Platzman Weinstock